A new therapeutic vaccine has demonstrated early potential in extending the lives of patients with aggressive brain tumors, according to a small German study. Two-thirds of participants were still alive eight years after enrollment, and 42% had seen no recurrence during that period, results from the long-term follow-up, published in the journal Nature, showed. The findings surprised even the researchers involved and suggest that vaccine-based approaches may offer a path to durable disease control in cancers that are notoriously difficult to treat.
The implications are significant for patients with aggressive brain tumors, who typically face poor prognoses and limited treatment options. The long-term survival data, while from a small study, provide a rationale for larger trials and for continued investment in immunotherapy strategies. As the study of how best to use vaccines against hard-to-treat brain cancers continues, other teams at firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also looking to develop more effective medicines that can move the dial in the field, according to a report on Read More>>.
The study’s results were reported by TinyGems, a communications platform focused on innovative small-cap and mid-cap companies. TinyGems is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. The platform also provides article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions.
With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer.
